Sorrento Therapeutics Inc (SRNE)

[dia76ca]

One great product producing revenue NOW.

*COVISTIX(COVIMARK): Marketing approval in Mexico, Brazil and Europe. Sales initially limited by low volume of production. Recently ramping up to 30 million a month range...and could exceed 50 million or more by year end.
Approval applications completed in Canada, US and World Health Organization. Affordable, 15 minute, highly accurate for all Covid variants. Could easily exceed $750 million in sales annually.

The next great product producing revenue by year end 2022.

*SEMDEXA:Great safety and efficacy results in pivotal Phase 3. Already has Fast Track, and will seek Breakthrough Designation and Priority Review before Mid-2022. These allow for approval within 6 months! Multi-Billion Sciatica market followed by many other indications estimated at an additional 50-200%.

These programs will finance the rest of the portfolio...COVISHIELD, Mpro, mRNA vaccine, ADNAB, DAR-T, RTX, SOFUSA etc. etc.